行情

JAGX

JAGX

Jaguar Health
NASDAQ

实时行情|Nasdaq Last Sale

1.380
-0.050
-3.50%
盘后: 1.410 +0.03 +2.17% 16:49 11/26 EST
开盘
1.400
昨收
1.430
最高
1.420
最低
1.350
成交量
79.61万
成交额
--
52周最高
13.41
52周最低
0.6240
市值
6,458.10万
市盈率(TTM)
-1.0447
分时
5日
1月
3月
1年
5年
BRIEF-Jaguar Health Files For Mixed Shelf Of Up To $75 Mln
reuters.com · 5天前
Jaguar Health's Posts Crofelemer Data For Chemo-Induced Diarrhea In Breast Cancer Patients
Jaguar Health Inc (NASDAQ: JAGX) 
Benzinga · 11/19 19:21
Jaguar Health Announces Topline Results Of Investigator-Initiated Phase 2 Study Of Crofelemer
 Jaguar Health, Inc. (NASDAQ:JAGX) today announced topline results of the third-party, investigator-initiated Phase 2 HALT-D trial evaluating crofelemer for the prevention of chemotherapy-induced diarrhea (CID) in
Benzinga · 11/19 14:23
Jaguar Health Announces Topline Results of Investigator-Initiated Phase 2 Study of Crofelemer for Prevention of Chemotherapy-Induced Diarrhea (CID) in Breast Cancer Patients
Crofelemer is a novel, oral plant-based non-opioid antidiarrheal medication SAN FRANCISCO, CA / ACCESSWIRE / November 19, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced topline results of the third-party, investigator-initiated Phase 2...
AccessWire · 11/19 14:20
研究 Jaguar Health 的资本使用回报
According to data from Benzinga Pro, during Q3, Jaguar Health's (NASDAQ:JAGX) reported sales totaled $630.00 thousand. Despite a 17.71% increase in earnings, the company posted a loss of $9.53 million.
Benzinga · 11/17 17:03
Jaguar Health: Q3 Earnings Insights
  Jaguar Health (NASDAQ:JAGX) reported its Q3 earnings results on Wednesday, November 17, 2021 at 08:00 AM. Here's what investors need to know about the announcement.
Benzinga · 11/17 13:45
Jaguar Health EPS misses by $0.10, misses on revenue
Jaguar Health (NASDAQ:JAGX): GAAP EPS of -$0.27 misses by $0.10. Revenue of $0.63M (-77.3% Y/Y) misses by $2.5M. Press Release Non-GAAP EBITDA was a net loss of $8.52M vs. a
Seekingalpha · 11/17 13:09
Jaguar Health Q3 EPS $(0.27) Misses $(0.17) Estimate, Sales $630.00K Miss $2.63M Estimate
Jaguar Health (NASDAQ:JAGX) reported quarterly losses of $(0.27) per share which missed the analyst consensus estimate of $(0.17) by 58.82 percent. This is a 57.14 percent increase over losses of $(0.63) per share from
Benzinga · 11/17 13:08
更多
财务预测
实际值(美元)
预测值(美元)
利润表更多
净利润(美元)
同比(%)
资产负债表更多
总资产(美元)
总负债(美元)
资产负债率(%)
现金流表更多
经营现金流(美元)
同比(%)
了解JAGX最新的财务预测,通过JAGX每股收益,每股净资产,每股现金流等数据分析Jaguar Health近期的经营情况,然后做出明智的投资选择。
分析师评级

2位分析师的综合评级

强力推荐

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

50.00%强力推荐
50.00%买入
0.00%中性
0.00%落后大盘
0.00%卖出
目标价格预测
分析师预测JAGX价格均价为10.88,最高价位15.00,最低价为6.75。
最高15.00
均价10.88
最低6.75
现价1.380
EPS
实际EPS
预期EPS
-0.36-0.27-0.18-0.09
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Q4 2021
机构持股
总机构数: 33
机构持股: 769.01万
持股比例: 16.43%
总股本: 4,679.79万
类型机构数股数
增持
11
174.40万
建仓
4
11.92万
减持
12
152.22万
平仓
10
4.83万
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
生物技术和医学研究
+2.30%
制药与医学研究
+0.44%
高管信息
Non-Executive Chairman/Independent Director
James Bochnowski
President/Chief Executive Officer/Director
Lisa Conte
Chief Financial Officer/Chief Accounting Officer
Carol Lizak
Executive Vice President
Karen Brunke
Chief Compliance Officer/General Counsel
Jonathan Wolin
Director of Marketing
Chip Whitlow
Secretary
Steven King
Independent Director
Gregory Divis
Independent Director
John Micek
Independent Director
Jonathan Siegel
暂无数据
JAGX 简况
Jaguar Health Inc是一家天然产品制药公司。该公司专注于在全球范围开发和商业化用于人类处方药和动物的新型可持续来源的胃肠产品。该公司通过其子公司Napo Pharmaceuticals Inc专注于从热带雨林地区的传统植物开发和商业化人类胃肠道药物,并面向全球市场。它的Mytesi是一种抗腹泻药,用于抗逆转录病毒疗法的人类免疫缺陷病毒HIV/获得性免疫缺陷综合症(AIDS)成年患者的非感染性腹泻症状缓解。其他产品包括Canalevia、Equilevia、Neorom Calf和Neonorm Foal。

微牛提供Jaguar Health Inc(NASDAQ-JAGX)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的JAGX股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易JAGX股票基本功能。